Shepherd Kaplan Krochuk
Shepherd Kaplan Krochuk, LLC is an employee-owned investment advisory firm based in Boston, Massachusetts, founded in 2001. The firm specializes in providing fiduciary management and investment services, focusing on pooled investment vehicles and investment companies. With over $6 billion in assets under management, Shepherd Kaplan Krochuk offers a range of services, including the management of equity and balanced mutual funds, hedge funds, and separate client-focused equity portfolios. The firm utilizes both fundamental and quantitative analysis to invest primarily in value stocks across global public equity and fixed income markets. By leveraging a team of experienced professionals and a proprietary technology platform, Shepherd Kaplan Krochuk aims to deliver institutional-level capabilities while maintaining a high standard of client service.
Trilio is a prominent provider of cloud-native data protection solutions specifically designed for Kubernetes, OpenStack, and Red Hat Virtualization environments. The company's flagship technology, TrilioVault, enables cloud infrastructure operators and developers to perform essential functions such as backup and recovery, workload migration, and application mobility. TrilioVault is utilized across various sectors, including telecommunications, defense, automotive, and financial services, allowing organizations to effectively recover from disasters, transition workloads, and migrate to new software distributions. The platform supports comprehensive data protection and management, offering capabilities for restoring entire workloads on-demand, ensuring business continuity in private, public, and hybrid cloud environments.
Windgap Medical
Series B in 2022
Windgap Medical Inc. is a biotechnology company that specializes in the manufacture of compact epinephrine autoinjectors designed for the treatment of anaphylaxis, a severe allergic reaction. Established in 2011, the company is headquartered in Watertown, Massachusetts. Windgap Medical's innovative auto-injectors are filled with heat-stable epinephrine, which enhances the temperature resilience and shelf life of the medication. This feature allows healthcare providers to effectively administer epinephrine to patients experiencing acute allergy attacks, improving their chances of recovery during critical moments.
Etiometry
Series A in 2021
Etiometry is a provider of advanced patient monitoring software designed specifically for hospital ICUs. The company's platform integrates and analyzes healthcare data, allowing clinicians to view comprehensive clinical information on a single screen. This functionality enhances objective communication among care teams and supports the identification of optimal treatment paths for ICU patients. The software consists of three interconnected components that not only deliver critical information for immediate patient care but also assess risk factors associated with deteriorating conditions. Additionally, it archives data for research and quality improvement initiatives, enabling healthcare institutions to gain valuable insights that facilitate the early recognition of subtle changes in patient condition, ultimately aiming to prevent complications and promote faster recovery.
Trilio is a prominent provider of cloud-native data protection solutions specifically designed for Kubernetes, OpenStack, and Red Hat Virtualization environments. The company's flagship technology, TrilioVault, enables cloud infrastructure operators and developers to perform essential functions such as backup and recovery, workload migration, and application mobility. TrilioVault is utilized across various sectors, including telecommunications, defense, automotive, and financial services, allowing organizations to effectively recover from disasters, transition workloads, and migrate to new software distributions. The platform supports comprehensive data protection and management, offering capabilities for restoring entire workloads on-demand, ensuring business continuity in private, public, and hybrid cloud environments.
NanoDx is a medical device start-up focused on developing portable, easy-to-use, and low-cost handheld products for the screening and monitoring of mild brain injuries, particularly concussions. The company aims to redefine how concussions are identified and managed by offering rapid testing that accurately confirms traumatic brain injuries. These innovative products allow patients who have experienced head trauma to receive timely and appropriate treatment decisions, which may help reduce the need for unnecessary head CT scans. Through its advancements, NanoDx is contributing to improved outcomes in the management of brain injuries.
Peak Capital Management
Acquisition in 2020
PCM develops disciplined, rules-based investment strategies designed to evaluate risk on a daily basis and adapt accordingly. PCM also advises high net worth families, pension and profit sharing plans, charitable organizations, and third-party advisors through portfolio management, research, and outsourced chief investment officer capabilities.
Windgap Medical
Corporate Round in 2019
Windgap Medical Inc. is a biotechnology company that specializes in the manufacture of compact epinephrine autoinjectors designed for the treatment of anaphylaxis, a severe allergic reaction. Established in 2011, the company is headquartered in Watertown, Massachusetts. Windgap Medical's innovative auto-injectors are filled with heat-stable epinephrine, which enhances the temperature resilience and shelf life of the medication. This feature allows healthcare providers to effectively administer epinephrine to patients experiencing acute allergy attacks, improving their chances of recovery during critical moments.
EnGeneIC Ltd is a biopharmaceutical company based in Lane Cove West, Australia, established in 2000. The company specializes in the development of a nano cell platform aimed at the targeted delivery of chemotherapeutics and functional nucleic acids for cancer treatment. Key to its approach is the EnGeneIC Dream Vector (EDV), a cyto-immunotherapy technology that employs antibody-targeted, bacterially derived, and non-living nano cells. This platform enables the release of high concentrations of chemotherapeutic agents, molecularly targeted drugs, and RNA-interference molecules directly into tumor cells. EnGeneIC's innovative technology seeks to enhance the effectiveness of cancer therapies while reducing toxicity, providing a potential solution for treating drug-resistant cancers. The company serves clients in various countries, including Australia, Singapore, Japan, and India.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.